AN INTEGRATED APPROACH TO POLYCYSTIC OVARY SYNDROME: DIAGNOSIS, PHARMACOLOGICAL TREATMENT AND BEHAVIOURAL INTERVENTIONS
Abstract
Introduction and Objective: Polycystic ovary syndrome (PCOS) is an endocrine disorder affecting women of all ages. PCOS is one of the most common causes of anovulatory infertility, affecting up to 47% of patients. This work aims to present diagnostic methods, the importance of lifestyle management, and treatment methods in women with PCOS.
Review Methods: A literature review was conducted using the PubMed database to identify relevant articles related to polycystic ovary syndrome (PCOS) using keywords: “Polycystic Ovary Syndrome”, “Polycystic Ovary Syndrome/diagnosis”, “Polycystic Ovary Syndrome/therapy”, “Phenotype”, “Infertility”, and “Life Style”.
Brief description of the state of knowledge: PCOS typically presents with hyperandrogenism, polycystic ovarian morphology, and oligoovulation. It also affects metabolism, body weight, cardiovascular and mental health. Diagnosis is based on the modified Rotterdam criteria, which require two of three conditions: oligo/amenorrhea, hyperandrogenism, or polycystic ovaries, while excluding similar disorders. Treatment should be individualized and address infertility, menstrual disturbances, or androgen-related symptoms. Lifestyle interventions, including diet, regular physical activity, and weight control, are the first-line strategy in PCOS management.
Summary: PCOS requires early diagnosis and individualized treatment tailored to the patient's symptoms and reproductive goals. Lifestyle modifications, including diet and physical activity, play a key role in improving hormonal balance, metabolic health, and fertility outcomes in affected women.
References
Bozdag, G., Mumusoglu, S., Zengin, D., Karabulut, E., & Yildiz, B. O. (2016). The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Human reproduction (Oxford, England), 31(12), 2841–2855. https://doi.org/10.1093/humrep/dew218
Azziz R. (2021). How polycystic ovary syndrome came into its own. F&S science, 2(1), 2–10. https://doi.org/10.1016/j.xfss.2020.12.007
Sirmans, S. M., & Pate, K. A. (2013). Epidemiology, diagnosis, and management of polycystic ovary syndrome. Clinical epidemiology, 6, 1–13. https://doi.org/10.2147/CLEP.S37559
Pasquali, R., Pelusi, C., Genghini, S., Cacciari, M., & Gambineri, A. (2003). Obesity and reproductive disorders in women. Human reproduction update, 9(4), 359–372. https://doi.org/10.1093/humupd/dmg024
Dunaif, A., Xia, J., Book, C. B., Schenker, E., & Tang, Z. (1995). Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome. The Journal of clinical investigation, 96(2), 801–810. https://doi.org/10.1172/JCI118126
Dunaif A. (1997). Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocrine reviews, 18(6), 774–800. https://doi.org/10.1210/edrv.18.6.0318
Joshi A. (2024). PCOS stratification for precision diagnostics and treatment. Frontiers in cell and developmental biology, 12, 1358755. https://doi.org/10.3389/fcell.2024.1358755
Christ, J. P., & Cedars, M. I. (2023). Current Guidelines for Diagnosing PCOS. Diagnostics (Basel, Switzerland), 13(6), 1113. https://doi.org/10.3390/diagnostics13061113
Franks S. (2008). Polycystic ovary syndrome in adolescents. International journal of obesity (2005), 32(7), 1035–1041. https://doi.org/10.1038/ijo.2008.61
Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group (2004). Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertility and sterility, 81(1), 19–25. https://doi.org/10.1016/j.fertnstert.2003.10.004
Teede, H. J., Tay, C. T., Laven, J. J. E., Dokras, A., Moran, L. J., Piltonen, T. T., Costello, M. F., Boivin, J., Redman, L. M., Boyle, J. A., Norman, R. J., Mousa, A., & Joham, A. E. (2023). Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. The Journal of clinical endocrinology and metabolism, 108(10), 2447–2469. https://doi.org/10.1210/clinem/dgad463
Teede, H. J., Misso, M. L., Costello, M. F., Dokras, A., Laven, J., Moran, L., Piltonen, T., Norman, R. J., & International PCOS Network (2019). Erratum. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Human reproduction (Oxford, England), 34(2), 388. https://doi.org/10.1093/humrep/dey363
Teede, H. J., Misso, M. L., Deeks, A. A., Moran, L. J., Stuckey, B. G., Wong, J. L., Norman, R. J., Costello, M. F., & Guideline Development Groups (2011). Assessment and management of polycystic ovary syndrome: summary of an evidence-based guideline. The Medical journal of Australia, 195(6), S65–S112. https://doi.org/10.5694/mja11.10915
Kim, C. H., Chon, S. J., & Lee, S. H. (2020). Effects of lifestyle modification in polycystic ovary syndrome compared to metformin only or metformin addition: A systematic review and meta-analysis. Scientific reports, 10(1), 7802. https://doi.org/10.1038/s41598-020-64776-w
Karimzadeh, M. A., & Javedani, M. (2010). An assessment of lifestyle modification versus medical treatment with clomiphene citrate, metformin, and clomiphene citrate-metformin in patients with polycystic ovary syndrome. Fertility and sterility, 94(1), 216–220. https://doi.org/10.1016/j.fertnstert.2009.02.078
Steinberg Weiss, M., Roe, A. H., Allison, K. C., Dodson, W. C., Kris-Etherton, P. M., Kunselman, A. R., Stetter, C. M., Williams, N. I., Gnatuk, C. L., Estes, S. J., Sarwer, D. B., Coutifaris, C., Legro, R. S., & Dokras, A. (2021). Lifestyle modifications alone or combined with hormonal contraceptives improve sexual dysfunction in women with polycystic ovary syndrome. Fertility and sterility, 115(2), 474–482. https://doi.org/10.1016/j.fertnstert.2020.08.1396
Rodriguez Paris, V., Solon-Biet, S. M., Senior, A. M., Edwards, M. C., Desai, R., Tedla, N., Cox, M. J., Ledger, W. L., Gilchrist, R. B., Simpson, S. J., Handelsman, D. J., & Walters, K. A. (2020). Defining the impact of dietary macronutrient balance on PCOS traits. Nature communications, 11(1), 5262. https://doi.org/10.1038/s41467-020-19003-5
Gautam, R., Maan, P., Jyoti, A., Kumar, A., Malhotra, N., & Arora, T. (2025). The Role of Lifestyle Interventions in PCOS Management: A Systematic Review. Nutrients, 17(2), 310. https://doi.org/10.3390/nu17020310
Nader, S., & Diamanti-Kandarakis, E. (2007). Polycystic ovary syndrome, oral contraceptives and metabolic issues: new perspectives and a unifying hypothesis. Human reproduction (Oxford, England), 22(2), 317–322. https://doi.org/10.1093/humrep/del407
Badawy, A., & Elnashar, A. (2011). Treatment options for polycystic ovary syndrome. International journal of women's health, 3, 25–35. https://doi.org/10.2147/IJWH.S11304
Li, J., Ren, J., & Sun, W. (2017). A comparative systematic review of Yasmin (drospirenone pill) versus standard treatment options for symptoms of polycystic ovary syndrome. European journal of obstetrics, gynecology, and reproductive biology, 210, 13–21. https://doi.org/10.1016/j.ejogrb.2016.11.013
Mathur, R., Levin, O., & Azziz, R. (2008). Use of ethinylestradiol/drospirenone combination in patients with the polycystic ovary syndrome. Therapeutics and clinical risk management, 4(2), 487–492. https://doi.org/10.2147/tcrm.s6864
Stańczak, N. A., Grywalska, E., & Dudzińska, E. (2024). The latest reports and treatment methods on polycystic ovary syndrome. Annals of medicine, 56(1), 2357737. https://doi.org/10.1080/07853890.2024.2357737
Collée, J., Mawet, M., Tebache, L., Nisolle, M., & Brichant, G. (2021). Polycystic ovarian syndrome and infertility: overview and insights of the putative treatments. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 37(10), 869–874. https://doi.org/10.1080/09513590.2021.1958310
Misso, M. L., Teede, H. J., Hart, R., Wong, J., Rombauts, L., Melder, A. M., Norman, R. J., & Costello, M. F. (2012). Status of clomiphene citrate and metformin for infertility in PCOS. Trends in endocrinology and metabolism: TEM, 23(10), 533–543. https://doi.org/10.1016/j.tem.2012.07.001
Balen, A. H., Morley, L. C., Misso, M., Franks, S., Legro, R. S., Wijeyaratne, C. N., Stener-Victorin, E., Fauser, B. C., Norman, R. J., & Teede, H. (2016). The management of anovulatory infertility in women with polycystic ovary syndrome: an analysis of the evidence to support the development of global WHO guidance. Human reproduction update, 22(6), 687–708. https://doi.org/10.1093/humupd/dmw025
Kousta, E., White, D. M., & Franks, S. (1997). Modern use of clomiphene citrate in induction of ovulation. Human reproduction update, 3(4), 359–365. https://doi.org/10.1093/humupd/3.4.359
Yang, A. M., Cui, N., Sun, Y. F., & Hao, G. M. (2021). Letrozole for Female Infertility. Frontiers in endocrinology, 12, 676133. https://doi.org/10.3389/fendo.2021.676133
Bansal, S., Goyal, M., Sharma, C., & Shekhar, S. (2021). Letrozole versus clomiphene citrate for ovulation induction in anovulatory women with polycystic ovarian syndrome: A randomized controlled trial. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 152(3), 345–350. https://doi.org/10.1002/ijgo.13375
Franik, S., Eltrop, S. M., Kremer, J. A., Kiesel, L., & Farquhar, C. (2018). Aromatase inhibitors (letrozole) for subfertile women with polycystic ovary syndrome. The Cochrane database of systematic reviews, 5(5), CD010287. https://doi.org/10.1002/14651858.CD010287.pub3
Legro, R. S., Brzyski, R. G., Diamond, M. P., Coutifaris, C., Schlaff, W. D., Casson, P., Christman, G. M., Huang, H., Yan, Q., Alvero, R., Haisenleder, D. J., Barnhart, K. T., Bates, G. W., Usadi, R., Lucidi, S., Baker, V., Trussell, J. C., Krawetz, S. A., Snyder, P., Ohl, D., … NICHD Reproductive Medicine Network (2014). Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. The New England journal of medicine, 371(2), 119–129. https://doi.org/10.1056/NEJMoa1313517
Orvieto, R., & Homburg, R. (2009). Chronic ultra-low dose follicle-stimulating hormone regimen for patients with polycystic ovary syndrome: one click, one follicle, one pregnancy. Fertility and sterility, 91(4 Suppl), 1533–1535. https://doi.org/10.1016/j.fertnstert.2008.09.009
Nugent, D., Vandekerckhove, P., Hughes, E., Arnot, M., & Lilford, R. (2000). Gonadotrophin therapy for ovulation induction in subfertility associated with polycystic ovary syndrome. The Cochrane database of systematic reviews, (4), CD000410. https://doi.org/10.1002/14651858.CD000410
Perales-Puchalt, A., & Legro, R. S. (2013). Ovulation induction in women with polycystic ovary syndrome. Steroids, 78(8), 767–772. https://doi.org/10.1016/j.steroids.2013.05.005
Balen A. H. (2013). Ovulation induction in the management of anovulatory polycystic ovary syndrome. Molecular and cellular endocrinology, 373(1-2), 77–82. https://doi.org/10.1016/j.mce.2012.10.008
Farquhar, C., Brown, J., & Marjoribanks, J. (2012). Laparoscopic drilling by diathermy or laser for ovulation induction in anovulatory polycystic ovary syndrome. The Cochrane database of systematic reviews, (6), CD001122. https://doi.org/10.1002/14651858.CD001122.pub4
Melo, A. S., Ferriani, R. A., & Navarro, P. A. (2015). Treatment of infertility in women with polycystic ovary syndrome: approach to clinical practice. Clinics (Sao Paulo, Brazil), 70(11), 765–769. https://doi.org/10.6061/clinics/2015(11)09
Debras, E., Fernandez, H., Neveu, M. E., Deffieux, X., & Capmas, P. (2019). Ovarian drilling in polycystic ovary syndrome: Long term pregnancy rate. European journal of obstetrics & gynecology and reproductive biology: X, 4, 100093. https://doi.org/10.1016/j.eurox.2019.100093
Sun, B., Ma, Y., Li, L., Hu, L., Wang, F., Zhang, Y., Dai, S., & Sun, Y. (2021). Factors Associated with Ovarian Hyperstimulation Syndrome (OHSS) Severity in Women With Polycystic Ovary Syndrome Undergoing IVF/ICSI. Frontiers in endocrinology, 11, 615957. https://doi.org/10.3389/fendo.2020.615957
Al-Inany, H. G., Youssef, M. A., Aboulghar, M., Broekmans, F., Sterrenburg, M., Smit, J., & Abou-Setta, A. M. (2011). Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. The Cochrane database of systematic reviews, (5), CD001750. https://doi.org/10.1002/14651858.CD001750.pub3
Kotlyar, A. M., & Seifer, D. B. (2023). Women with PCOS who undergo IVF: a comprehensive review of therapeutic strategies for successful outcomes. Reproductive biology and endocrinology : RB&E, 21(1), 70. https://doi.org/10.1186/s12958-023-01120-7
Walls, M. L., & Hart, R. J. (2018). In vitro maturation. Best practice & research. Clinical obstetrics & gynaecology, 53, 60–72. https://doi.org/10.1016/j.bpobgyn.2018.06.004
Patel S. (2018). Polycystic ovary syndrome (PCOS), an inflammatory, systemic, lifestyle endocrinopathy. The Journal of steroid biochemistry and molecular biology, 182, 27–36. https://doi.org/10.1016/j.jsbmb.2018.04.008
Naderpoor, N., Shorakae, S., de Courten, B., Misso, M. L., Moran, L. J., & Teede, H. J. (2016). Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis. Human reproduction update, 22(3), 408–409. https://doi.org/10.1093/humupd/dmv063
Morley, L. C., Tang, T., Yasmin, E., Norman, R. J., & Balen, A. H. (2017). Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. The Cochrane database of systematic reviews, 11(11), CD003053. https://doi.org/10.1002/14651858.CD003053.pub6
Tasdemir, S., Ficicioglu, C., Yalti, S., Gurbuz, B., Basaran, T., & Yildirim, G. (2004). The effect of metformin treatment to ovarian response in cases with PCOS. Archives of gynecology and obstetrics, 269(2), 121–124. https://doi.org/10.1007/s00404-002-0447-8
Fruzzetti, F., Perini, D., Russo, M., Bucci, F., & Gadducci, A. (2017). Comparison of two insulin sensitizers, metformin and myo-inositol, in women with polycystic ovary syndrome (PCOS). Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 33(1), 39–42. https://doi.org/10.1080/09513590.2016.1236078
Greff, D., Juhász, A. E., Váncsa, S., Váradi, A., Sipos, Z., Szinte, J., Park, S., Hegyi, P., Nyirády, P., Ács, N., Várbíró, S., & Horváth, E. M. (2023). Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. Reproductive biology and endocrinology : RB&E, 21(1), 10. https://doi.org/10.1186/s12958-023-01055-z
Rashid, R., Mir, S. A., Kareem, O., Ali, T., Ara, R., Malik, A., Amin, F., & Bader, G. N. (2022). Polycystic ovarian syndrome-current pharmacotherapy and clinical implications. Taiwanese journal of obstetrics & gynecology, 61(1), 40–50. https://doi.org/10.1016/j.tjog.2021.11.009
Falsetti, L., Gambera, A., Platto, C., & Legrenzi, L. (2000). Management of hirsutism. American journal of clinical dermatology, 1(2), 89–99. https://doi.org/10.2165/00128071-200001020-00003
Views:
11
Downloads:
3
Copyright (c) 2025 Aleksandra Dzwonkowska, Paulina Redel
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
